All funds raised will go 100% to researchers. This project is a multi-year collaboration between Project Lyme, the Bay Area Lyme Foundation, and Sapient.
Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery with its research aimed at establishing new diagnostics for persistent Lyme disease (PLD).
The report shares insight into the research being conducted by Sapient in leveraging the Lyme Disease Biobank to discover circulating biomarkers related to PLD, as well as circulating protective biomarkers related to lifestyle, diet, and environmental exposures. Initial analysis has led to the discovery of novel diagnostic biomarkers which may potentially be developed to screen individuals at risk for chronic, persistent Lyme disease.Lyme disease is the fastest growing vector-borne illness in the US. The current gold standard diagnostic for Lyme, a two-tiered ELISA/Western Blot blood test, misses up to 60% of early-stage cases, with many individuals going undiagnosed and untreated. Up to 30% of these patients ultimately develop PLD, with chronic, severe, and debilitating symptoms.
“Our biomarker discovery platform enables high-throughput, untargeted profiling of tens of thousands of molecules in blood, providing an unprecedented view into the biomarker disruptions involved in Lyme disease,” said Mohit Jain, MD, PhD, Founder and CEO of Sapient. “The discoveries we’ve made so far are extremely compelling, not only for better disease diagnosis but also for understanding how protective biomarkers can be used in Lyme treatments. We’re excited to continue our partnership with Bay Area Lyme Foundation to translate these findings to the clinic.”
Sapient is an end-to-end biomarker discovery partner for pharmaceutical and biotechnology sponsors. Its platform combines advanced mass spectrometry technologies – able to assay >11,000 molecules per biosample – computational learning, and an expansive proprietary Human Biology Database of >300,000 individuals to discover and validate circulating biomarkers at unprecedented speed and scale, and rapidly deliver actionable insights that align patients, disease biology, and specific therapies.
These methods reduce the time and complexity of biomarker discovery and validation at any phase, and drive greater understanding of biological processes, disease progression, and drug responsiveness to optimize drug pipelines and accelerate clinical development. For more information, visit sapient.bio.
Science
06/27/2023
A recent Washington Post article asked a doctor, "A tick bit me. What do I do now?". The responses included false or potentially misleading information, so we decided to address the issues in order to help patients avoid confusion.
Science
06/19/2023
There are 15 different tick-borne diseases, including the topic of this article, Bartonella. The ability of ticks to harbor and transmit Bartonella has been heartily debated for years because of the lack of direct, conclusive evidence. This blog works to dispel this debate by sharing existing research in order to outline why both patients and medical care providers should consider Bartonella as part of the differential diagnosis.
Science
06/02/2023
Lyme disease has the potential to impact nearly every single system in our body including our brain, gut, endocrine system, nervous system, reproductive system, and cardiovascular system. This is why it can lead to such widespread symptoms that can vary from person to person. One of the major impacts it can have is on your endocrine system, which can impact thyroid function, adrenal function, and overall hormonal balance in the body. Dr. Izabella Wentz, author of Adrenal Transformation Protocol, addresses these issues and how to solve them.
